In this issue of Blood, Xiao et al provide a direct link between the OTT protein and regulation of splicing of the RNA for c-MPL, which encodes the thrombopoietin receptor.
1
O TT was first identified as part of the recurrent t(1;22) translocation in acute megakaryoblastic leukemia (AMKL) and was called OTT for "one twenty-two." OTT1 is also known as RNA binding motif protein 15 (RBM15). Like other RNA binding motif proteins, RBM15 contains RNA recognition motifs (RRMs), 3 in total, which can bind to RNA and, at least for some RRMs, may also bind to DNA. Lifelong maintenance of hematopoietic stem cell (HSC) numbers is essential, and the genes for Ott and for Mpl are required for such maintenance. In prior studies from Dr Glen Raffel's laboratory at the University of Massachusetts and other laboratories, Rbm15 expression was shown to be critical for maintenance of HSCs in vivo in mice under stress. 
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In this issue of Blood, Mir et al present data on the prognostic role of cytokines, chemokines, and their ligands measured in serum in patients with follicular lymphoma (FL).
1 This lymphoma has a variable course, and reliable markers for predicting outcome are needed. The entire composition of the microenvironment and the architectural pattern (and not individual subsets) might be best associated with outcome. 5, 6 However, data on the prognostic importance of the tumor microenvironment are conflicting, mainly due to heterogeneity in study design and end points, patient selection, and technical aspects of immune cell quantification (flow cytometry or immunohistochemistry with manual or computer-assisted scoring), 7 and because patients are heterogeneously treated. 8 As an example, the addition of the monoclonal anti-CD20 antibody, rituximab, to chemotherapy, has been shown to abrogate the negative impact of macrophages.
9
Serum markers have previously been suggested to contribute to or mirror the tumor microenvironment in FL.
10 Serum levels of IL-1R1, IL-6, IL-7, IL-10, IL-13, TNF-a, vascular endothelial growth factor (VEGF), and platelet-derived growth factor were increased in 60 FL patients compared with controls. Multivariate analysis identified early stage and high TGF-b levels as independent predictors of improved overall survival, while high lactate dehydrogenase and VEGF levels were independently associated with poorer progression-free survival.
10
Mir et al now report data on serum levels of multiple cytokines and chemokines, and their receptors, in 2 large patient cohorts.
1
They have used a multiplex enzyme-linked immunosorbent assay and found that elevated levels of IL-2R, IL-1R1, and CXCL9 are associated with shorter event-free survival (EFS) in FL patients treated with chemotherapy or chemoimmunotherapy, whereas IL-1R1 and also IL-12 were associated with a shorter EFS in patients in a wait-and-watch cohort, as well as in patients treated with rituximab monotherapy. These serum factors seem independent of the FL international prognostic index, a validated prognosticator, and might be of great clinical impact, especially as they are easily accessible in blood.
The same research group has previously shown that soluble IL-2Ra facilitates IL-2-mediated immune responses and that elevated soluble IL-2R levels before treatment were associated with reduced survival in FL patients. 11 The prognostic relevance of these findings are now extended to more serum markers in 209 patients, prospectively enrolled on the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource and confirmed in a meta-analysis, also including 183 patients from 3 South West Oncology Group trials.
A problem with the interpretation of the data is that the endpoint used is EFS, which might not be solid enough, and no survival data are presented. The predictive effect of the level of serum markers on response to anti-CD20 antibodies, in this report rituximab, cannot be evaluated because the results are not presented in relation to rituximab administration. Patients with wait-and-watch are grouped together with those receiving rituximab monotherapy and no delineation is made between those with rituximab1chemotheraphy vs those few with chemotherapy alone.
The conclusion that IL-12 and IL-1R1 are predictive for poor outcome in FL patients who are initially observed (or getting rituximab monotherapy) is of interest, but prospective trials are needed to evaluate if early immunochemotherapy will affect the prognosis for patients with such high levels.
In newly diagnosed patients treated with more intensive regimens, Mir et al found that the elevated IL-2R is associated with short EFS.
1 The role of cytokines in lymphoma biology seems complex. A subset of lymphoma B cells express the IL-2R, and IL-2 is a critical homeostatic cytokine required for development, expansion, and activity of regulatory T cells. IL-2 is also necessary for the development of cytotoxic
